New treatment for severe corneal inflammation from DED now listed on PBS
Retrieved on:
Thursday, September 30, 2021
Narrative, News, Medical Affairs Bureau, TFOS, DED, PBS, Man, Duane syndrome, Optometry, Vaccine, International Regional Science Review, Diagnosis, Food, School, Patient, CSL, Inflammation, Health, S, Journal of Internal Medicine, Keratitis, TGA, Adult, S4, Matilde Leonardi, Classification, Professional services, Immune system, The National Interest, Itchy, Barabino, Current, Woman, Disease, Glass, Impact, Ophthalmology, COVID-19, Pharmaceutical Benefits Scheme, Safety, UNSW, Screen time, Time, George, Eye, Cornea, Pharmaceutical industry, Telescopic sight, Animal, Phosphorus, Health insurance, Medical device
(8,9)
Key Points:
- (8,9)
MELBOURNE, Oct 1, 2021 - (ACN Newswire) - Today, adults living with severe corneal inflammation from DED (dry eye disease) gain access to a new treatment on the PBS. - Ikervis(R), Australia's first PBS listed disease-modifying ciclosporin eye drop treatment for severe keratitis in adults with DED, is now available (October 1, 2021).
- "Artificial tears aim to provide symptom relief for DED, but don't address the underlying cause of severe corneal inflammation.
- Executive Chair of The B Team Australasia, Lynette has spent the past 16 years living with severe corneal inflammation from DED.